Uncategorized
Actavis reports first-quarter growth following Allergan acquisition
Actavis announced a 59% increase in net revenue for the quarter ending March 31, 2015, to $4.23 billion compared with $2.66 billion in the first quarter of 2014, according to a press release.“Actavis achieved exceptional operational performance while simultaneously focusing on the completion of the Allergan acquisition and accelerating the integration of our combined company to create a growth-pharma leader,” Brent Saunders, CEO and president of Actavis, said in the release.